Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and ...

Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, will ...

Insights from ASH 2025, including anticipated presentations, key takeaways, and how new research in chronic lymphocytic ...

For most of us, a cancer diagnosis would be the worst possible news. But a remarkable new documentary, Second Winds, captures ...

The treatment effects on PFS were consistent regardless of modeling approach and for both targeted and nontargeted therapies.

Chronic lymphocytic leukemia (CLL) starts in bone marrow, the soft inner part of your bones. There are some key differences that set CLL apart from other types of leukemia, such as ALL (acute ...

Lori A. Leslie, MD, and Hoshiyuki Iida, APN, provide an overview of chronic lymphocytic leukemia and the risk stratification process. Lori A. Leslie, MD: Hello, and welcome to CURE Expert Connections® ...

Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and ...

Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL) are types of blood cancer. They develop in types of white blood cells called B cells or T cells, or the precursors to these cells.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data across multiple ...

Leukemia is a cancer that changes blood cells. It usually develops in the bone marrow, the inner part of the bone that makes ...